Skip to main content

Table 2 Subgroup analysis of VEGF levels in AML

From: Increased circulating vascular endothelial growth factor in acute myeloid leukemia patients: a systematic review and meta-analysis

Stratification groupNSMD (95% CI)Heterogeneity testPublication bias
QPI2 (%)tP
Total140.85 (0.28 to 1.42)146.87< 0.00191.1− 0.750.467
Sample size       
n ≥ 4060.95 (0.14 to 1.77)66.45< 0.00192.5− 1.130.321
n < 4080.77 (− 0.11 to 1.65)80.21< 0.00191.3− 0.920.392
Sample type       
 Plasma80.80 (0.16 to 1.44)70.81< 0.00190.1− 0.850.430
 Serum60.93 (− 0.28 to 2.14)75.64< 0.00193.4− 0.660.545
Region       
 Asia and Africa111.09 (0.39 to 1.80)119.16< 0.00191.6− 0.220.828
 Europe and America30.01 (− 0.28 to 0.31)0.060.9700.05.410.116
Age       
 Age ≥ 4522.05 (0.06 to 4.04)19.71< 0.00194.9NANA
 Age < 4550.15 (− 0.64 to 0.93)29.89< 0.00186.60.570.610
 Combined70.69 (− 0.23 to 1.62)89.84< 0.00193.30.250.809
  1. N number, SMD standard mean difference, CI confidence interval, AML acute myeloid leukemia, VEGF vascular endothelial growth factor